Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

点击翻译按钮获取中文摘要

During this period, the NCATS group, as part of the LDHA collaborative team, has worked to pursue medicinal chemistry to further refine compound potencies and characterize lead molecules in a number of advanced cell-based assays. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.